Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) subsidiaries Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for injectable SHR-A2009 and adbelimab injections. Clinical trials will be carried out in the near future.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) subsidiaries Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for injectable SHR-A2009 and adbelimab injections. Clinical trials will be carried out in the near future.